PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8559-8581

  Cushing, Timothy D ^a   Metz, Daniela P ^a   Whittington, Douglas A ^a   McGee, Lawrence R ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; ANTIASTHMATIC AGENT; G PROTEIN COUPLED RECEPTOR; GSG 2269557; GSK 2269557; IDELALISIB; INTELLIKINE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; PICTILISIB; PROTEIN SERINE THREONINE KINASE; QUINAZOLINONE DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG; WORTMANNIN;

ASTHMA; AUTOIMMUNE DISEASE; BREAST CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; INFLAMMATORY DISEASE; LARGE CELL LYMPHOMA; LIPOPHILICITY; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; HUMANS; INFLAMMATION; ISOENZYMES; MOLECULAR TARGETED THERAPY; NEUTROPHILS; PROTEIN CONFORMATION; T-LYMPHOCYTES;

EID: 84867795025     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300847w     Document Type: Review

References (196)

1. Kong, D.; Yamori, T. Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors Curr. Med. Chem. 2009, 16, 2839-2854
2. Ameriks, M.; Venable, J. D. Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ Curr. Top. Med. Chem. 2009, 738-753
3. Sundstrom, T. J.; Anderson, A. C.; Wright, D. L. Inhibitors of Phosphoinositide-3-kinase: A Structure-Based Approach to Understanding Potency and Selectivity Org. Biomol. Chem. 2009, 7, 840-850
4. Parker, P. J. The Ubiquitous Phosphoinositides Biochem. Soc. Trans. 2004, 32, 893-898
5. Hawkins, P. T.; Anderson, K. E.; Davidson, K.; Stephens, L. R. Signaling through Class 1 PI3Ks in Mammalian Cells Biochem. Soc. Trans. 2006, 34, 647-662
6. Fruman, D. A.; Bismuth, G. Fine Tuning the Immune Response with PI3K Immunol. Rev. 2009, 228, 253-272
7. McInnes, I. B.; Schett, G. Cytokines in the Pathogenesis of Rheumatoid Arthritis Nat. Rev. Immunol. 2007, 7, 429-442
8. Mount, G. R.; Gilliland, W. R. Emerging Biological Therapies in Systemic Lupus Erythematosus Clin. Pharmacol. Ther. 2008, 83, 167-171
9. Compston, A.; Coles, A. Multiple Sclerosis Lancet 2008, 372, 1502-1517
10. Lowes, M. A.; Bowcock, A. M.; Krueger, J. G. Pathogenesis and Therapy of Psoriasis Nature 2007, 445, 866-873
11. Decramer, M.; Janssens, W.; Miravitlles, M. Chronic Obstructive Pulmonary Disease Lancet 2012, 379, 1341-1351
12. Reutershan, J.; Saprito, M. S.; Wu, D.; Rückle, T.; Ley, K. Phosphoinositide 3- Kinase γ Required for Lipopolysaccharide-Induced Transepithelial Neutrophil Trafficking in the Lung Eur. Respir. J. 2010, 35, 1137-1147
13. Holgate, S. T.; Davies, D. E. Rethinking the Pathogenesis of Asthma Immunity 2009, 31, 362-367
14. King, T. E., Jr.; Pardo, A.; Selman, M. Idiopathic Pulmonary Fibrosis Lancet 2011, 378, 1949-1961
15. Xavier, R. J.; Podolsky, D. K. Unravelling the Pathogenesis of Inflammatory Bowel Disease Nature 2007, 448, 427-434
16. Hori, M.; Nishida, K. Oxidative Stress and Left Ventricular Remodelling after Myocardial Infarction Cardiovasc. Res. 2009, 81, 457-464
17. Bonjouklian, R.; Vlahos, C. J.; Powis, G. Inhibition of Phosphatidylinositol 3-Kinase with Wortmannin and Its Analogs. U.S. Patent 5,378,725, Jan 3, 1995.
18. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4 H -1-benzopyran-4-one (LY294002) J. Biol. Chem. 1994, 269, 5241-5248
19. Sadhu, C.; Dick, K.; Treiberg, J.; Sowell, C. G.; Kesicki, E. A.; Oliver, A. Quinazolinone Derivatives as Inhibitors of Human Phosphatidylinositol 3-Kinase delta. WO2001081346A2, 2001.
20. Pomel, V.; Klicic, J.; Covini, D.; Church, D. D.; Shaw, J. P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; Camps, M.; Chabert, C.; Gillieron, C.; Francon, B.; Perrin, D.; Leroy, D.; Gretener, D.; Nichols, A.; Vitte, P. A.; Carboni, S.; Rommel, C.; Schwarz, M. K.; Rückle, T. Furan-2-ylmethylene thiazolidinediones as Novel, Potent, and Selective Inhibitors of Phosphoinositide 3-Kinase γ J. Med. Chem. 2006, 49, 3857-3871
21. Camps, M.; Rückle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Francon, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy, D.; Vitte, P. A.; Hirsch, E.; Wymann, M. P.; Cirillo, R.; Schwarz, M. K.; Rommel, C. Blockade of PI3Kγ Suppresses Joint Inflammation and Damage in Mouse Models of Rheumatoid Arthritis Nat. Med. 2005, 11, 936-943
22. Wrasidlo, W.; Doukas, J.; Royston, I.; Noronha, G.; Hood, J. D.; Dneprovskaia, E.; Gong, X.; Splittgerber, U.; Zhao, N. Preparation of Vasculostatic Agents and Methods of Use. WO2004030635A2, 2004.
23. Okkenhaug, K.; Bilancio, A.; Farjot, G.; Priddle, H.; Sancho, S.; Peskett, E.; Pearce, W.; Meek, S. E.; Salpekar, A.; Waterfield, M. D.; Smith, A. J. H.; Vanhaesebroeck, B. Impaired B and T Cell Antigen Receptor Signaling in p110 delta PI 3-Kinase Mutant Mice Science 2002, 297, 1031-1034
24. Hirsch, E.; Katanaev, V. L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.; Altruda, F.; Wymann, M. P. Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation Science 2000, 287, 1049-1053
25. Patrucco, E.; Notte, A.; Barberis, L.; Selvetella, G.; Maffei, A.; Brancaccio, M.; Marengo, S.; Russo;, G.; Azzolino, O.; Rybalkin, S. D.; Silengo, L.; Altruda, F.; Wetzker, R.; Wymann, M. P.; Lembo, G.; Hirsch, E. PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects Cell 2004, 118, 375-387
26. Ji, H.; Rintelen, F.; Waltzinger, C.; Meier, D. B.; Bilancio, A.; Pearce, W.; Hirsch, E.; Wymann, M. P.; Rückle, T.; Camps, M.; Vanhaesebroeck, B.; Okkenhaug, K.; Rommel, C. Inactivation of PI3Kγ and PI3Kδ Distorts T-Cell Development and Causes Multiple Organ Inflammation Blood 2007, 110, 2940-2947
27. Wright, H. L.; Moots, R. J.; Bucknall, R. C.; Edwards, S. W. Neutrophil Function in Inflammation and Inflammatory Diseases Rheumatology 2010, 49, 1618-1631
28. Edwards, J. C. W.; Cambridge, G. Sustained Improvement in Rheumatoid Arthritis following a Protocol Designed To Deplete B Lymphocytes Rheumatology 2001, 40, 205-211
29. Yanaba, K.; Hamaguchi, Y.; Venturi, G. M.; Steeber, D. A., St.; Clair, E. W.; Tedder, T. F. B Cell Depletion Delays Collagen-Induced Arthritis in Mice: Arthritis Induction Requires Synergy between Humoral and Cell-Mediated Immunity J. Immunol. 2007, 179, 1369-1380
30. Li, J; Kuzin, I; Moshkani, S; Proulx, S. T.; Xing, L; Skrombolas, D.; Dunn, R.; Sanz, I; Schwarz, E. M.; Bottaro, A. Expanded CD23+/CD21hi B Cells in Inflamed Lymph Nodes Are Associated with the Onset of Inflammatory-Erosive Arthritis in TNF-Transgenic Mice and Are Targets of Anti-CD20 Therapy J. Immunol. 2010, 184, 6142-6150
31. Rituximab was found to be ineffective in a large scale phase II/III clinical trial for SLE.
32. Vallerskog, T.; Gunnarsson, I.; Widhe, M.; Risselada, A.; Klareskog, L.; van Vollenhoven, R.; Malmström, V.; Trollmo, C. Treatment with Rituximab Affects Both the Cellular and the Humoral Arm of the Immune System in Patients with SLE Clin. Immunol. 2007, 122, 62-74
33. Ferrandi, C.; Ardissone, V.; Ferro, P.; Rückle, T.; Zaratin, P.; Ammannati, E.; Hauben, E.; Rommel, C.; Cirillo, R. Phosphoinositide 3-Kinase γ Inhibition Plays a Crucial Role in Blocking the Early Steps of Inflammation by Blocking Neutrophil Recruitment J. Pharmacol. Exp. Ther. 2007, 322, 923-930
34. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A Pharmacological Map of the PI3-K Family Defines a Role for P110α in Insulin Signaling Cell 2006, 125, 733-747
35. Palanki, M. S. S.; Dneprovskaia, E.; Doukas, J.; Fine, R.,M.; Hood, J.; Kang, X.; Lohse, D.; Martin, M.; Noronha, G.; Soll, R. M.; Wrasidlo, W.; Yee, S.; Zhu, H. Discovery of 3,3′-(2,4-Diaminopteridine-6,7-diyl)diphenol as an Isozyme-Selective Inhibitor of PI3K for the Treatment of Ischemia Reperfusion Injury Associated with Myocardial Infarction J. Med. Chem. 2007, 18, 4279-4294
36. Soond, D. R.; Bjrgo, E.; Moltu, K.; Dale, V. Q.; Patton, D. T.; Torgerson, K. M.; Galleway, F.; Twomey, B.; Clark, J.; Gaston, J. S. H.; Taskén, K.; Bunyard, P.; Okkenhaug, K. PI3K P110δ Regulates T-Cell Cytokine Production During Primary and Secondary Immune Responses in Mice and Humans Blood 2010, 115, 2203-2213
37. Sasaki, T.; Irie-Sasaki, J.; Jones, R. G.; Oliveira-dos-Santos, A. J.; Stanford, W. L.; Bolon, B.; Wakeham, A.; Itie, A.; Bouchard, D.; Kozieradzki, I.; Joza, N.; Mak, T. W.; Ohashi, P. S.; Suzuki, A.; Penninger, J. M. Function of PI3Kγ in Thymocyte Development, T Cell Activation, and Neutrophil Migration Science 2000, 287, 1040-1046
38. Alcázar, I.; Marqués, M.; Kumar, A.; Hirsch, E.; Wymann, M.; Carrera, A. C.; Barber, D. F. Phosphoinositide 3-Kinase γ Participates in T cell Receptor-Induced T Cell Activation J. Exp. Med. 2007, 204, 2977-2987
39. Curnock, A. P.; Sotsios, Y.; Wright, K. L.; Ward, S. G. Optimal Chemotactic Responses of Leukemic T Cells to Stromal Cell-Derived Factor-1 Requires the Activation of Both Class 1A and Class 1B Phosphoinositide 3-Kinases J. Immunol. 2003, 170, 4021-4030
40. Smith, L. D.; Hickman, E. S.; Parry, R. V.; Westwick, J.; Ward, S. G. PI3Kγ Is the Dominant Isoform Involved in Migratory Responses of Human T Lymphocytes: Effects of ex Vivo Maintenance and Limitations of Non-Viral Delivery of siRNA Cell. Signalling 2007, 19, 2528-2539
41. Sadhu, C.; Masinovsky, B.; Dick, K.; Sowell, C. G.; Staunton, D. E. Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement J. Immunol. 2003, 170, 2647-2654
42. Puri, K. D.; Doggett, T. A.; Douangpanya, J.; Hou, Y.; Tino, W. T.; Wilson, T.; Graf, T.; Clayton, E.; Turner, M.; Hayflick, J. S.; Diacovo, T. G. Mechanism and Implications of Phosphoinositide 3-Kinase delta in Promoting Neutrophil Trafficking into Inflamed Tissue Blood 2004, 103, 3448-3456
43. Ali, K.; Bilancio, A.; Thomas, M.; Pearce, W.; Gilfillan, A. M.; Tkaczyk, C.; Kuehn, N.; Gray, A.; Giddings, J.; Peskett, E.; Fox, R.; Bruce, I.; Walker, C.; Sawyer, C.; Okkenhaug, K.; Finan, P.; Vanhaesebroeck, B. Essential Role for the P110δ Phosphoinositide 3-Kinase in the Allergic Response Nature 2004, 431, 1007-1011
44. Ali, K.; Camps, M.; Pearce, W. P.; Ji, H.; Rückle, T.; Kuehn, N.; Pasquali, C.; Chabert, C.; Rommel, C.; Vanhaesebroeck, B. Isoform-Specific Functions of Phosphoinositide 3-Kinases: PI3Kδ but not PI3Kγ Promotes Optimal Allergic Responses in Vivo J. Immunol. 2008, 180, 2538-2544
45. Laffargue, M.; Calvez, R.; Finan, P.; Trifilieff, A.; Barbier, M.; Altruda, F.; Hirsch, E.; Wymann, M. P. Phosphoinositide 3-Kinase γ Is an Essential Amplifier of Mast Cell Function Immunity 2002, 16, 441-451
46. Thomas, M.; Edwards, M. J.; Sawicka, E.; Duggan, N.; Hirsch, E.; Wymann, M. P.; Owen, C.; Trifilieff, A.; Walker, C.; Westwick, J.; Finan, P. Essential Role of Phosphoinositide 3-Kinase gamma in Eosinophil Chemotaxis within Acute Pulmonary Inflammation Immunology 2009, 126, 413-422
47. Takeda, M.; Ito, W.; Tanabe, M.; Ueki, S.; Kato, H.; Kihara, J.; Tanigai, T.; Chiba, T.; Yamaguchi, K.; Kayaba, H.; Imai, Y.; Okuyama, K.; Ohno, I.; Sasaki, T.; Chihara, J. Allergic Airway Hyperresponsiveness, Inflammation, and Remodeling Do Not Develop in Phosphoinositide 3-Kinase γ-Deficient Mice J. Allergy Clin. Immunol. 2009, 123, 805-812
48. Kang, B. N.; Ha, S. G.; Ge, X. N.; Hosseinkhani, M. R.; Bahaie, N. S.; Greenberg, Y.; Blumenthal, M. N.; Puri, K. D.; Rao, S. P.; Sriramarao, P. The p110δ Subunit of PI3K Regulates Bone Marrow-Derived Eosinophil Trafficking and Airway Eosinophilia in Allergen-Challenged Mice Am J. Physiol.: Lung Cell. Mol. Physiol. 2012, 302, 1179-1191
49. Doukas, J.; Eide, L.; Stebbins, K.; Racanelli-Layton, A.; Dellamary, L.; Martin, M.; Dneprovskaia, E.; Noronha, G.; Soll, R.; Wrasidlo, W.; Acevedo, L. M.; Cheresh, D. A. Aerosolized Phosphoinositide 3-Kinase γ/δ Inhibitor TG100-115 [3-[2,4-Diamino-6-(3-hydroxyphenyl)-pteridin-7-yl]phenol] as a Therapeutic Candidate for Asthma and Chronic Obstructive Pulmonary Disease J. Pharmacol. Exp. Ther. 2009, 328, 758-765
50. Ghigo, A.; Damilano, F.; Braccini, L.; Hirsch, E. PI3K Inhibition in Inflammation: Toward Tailored Therapies for Specific Diseases BioEssays 2010, 32, 185-196
51. Costa, C.; Martin-Conte, E. L.; Hirsch, E. Phosphoinositide 3-Kinase p110γ in Immunity IUBMB Life 2011, 63, 707-713
52. Fung-Leung, W. P. Phosphoinositide 3-Kinase delta (PI3Kδ) in Leukocyte Signaling and Function Cell. Signalling 2011, 23, 603-608
53. Lee, K. S.; Lee, H. K.; Hayflick, J. S.; Lee, Y. C.; Puri, K. D. Inhibition of Phosphoinositide 3-Kinase delta Attenuates Allergic Airway Inflammation and Hyperresponsiveness in Murine Asthma Model FASEB J. 2006, 20, 455-465
54. Shimada, M.; Murata, T.; Fuchikami, K.; Tsujishita, H.; Omori, N.; Kato, I.; Miura, M.; Urbahns, K.; Gantner, F.; Bacon, K. Preparation of Fused Azole-pyrimidine Derivatives as PI3K Inhibitors with Therapeutic Uses. WO2004029055A1, 2004.
55. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F. I.; Workman, P.; Waterfield, M. D.; Parker, P. Synthesis and Biological Evaluation of Pyrido[3′,2′:4,5]furo[3,2- d ]pyrimidine Derivatives as Novel PI3 Kinase P110α Inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2438-2442
56. A- PI3K-Induced Systemic Lupus but Not T Cell Invasion J. Immunol. 2006, 176, 589-593
57. Martin, A. L.; Schwartz, M. D.; Jameson, S. C.; Shimizu, Y. Selective Regulation of CD8 Effector T Cell Migration by the p110γ Isoform of Phophatidylinositol 3-Kinase J. Immunol. 2008, 180, 2081-2088
58. Patton, D. T.; Garden, O. A.; Pearce, W. P.; Clough, L. E.; Monk, C. R.; Leung, E.; Rowan, W. C.; Sancho, S.; Walker, L. S. K.; Vanhaesebroeck, B.; Okkenhaug, K. Cutting Edge: The Phosphoinositide 3-Kinase p110δ Is Critical for the Function of CD4+CD25+Foxp3+ Regulatory T Cells J. Immunol. 2006, 177, 6598-6602
59. Zhang, T. T.; Okkenhaug, K.; Nashed, B. F.; Puri, K. D.; Knight, Z. A.; Shokat, K. M.; Vanhaesebroeck, B.; Marshall, A. J. Genetic or Blockade of P110δ Phosphoinositide 3-Kinase Enhances IgE Production J. Allergy Clin. Immun. 2008, 122 (4) 811-819
60. Park, S. J.; Lee, K. S.; Kim, S. R.; Min, K. H.; Moon, H.; Lee, M. H.; Chung, C. R.; Han, H. J.; Puri, K. D.; Lee, Y. C. Phosphoinositide 3-Kinase δ Inhibitor Suppresses Interleukin-17 Expression in a Murine Asthma Model Eur. Respir. J. 2010, 36, 1448-1459
61. Marwick, J. A.; Caramori, G.; Stevenson, C. S.; Casolari, P.; Jazrawi, E.; Barnes, P. J.; Ito, K.; Adcock, I. M.; Kirkham, P. A.; Papi, A. Inhibition of PI3Kδ Restores Glucocorticoid Function in Smoking Induced Airway Inflammation in Mice Am. J. Respir. Crit. Care Med. 2009, 179, 542-548
62. Wei, X.; Han, J.; Chen, Z. Z.; Qi, B.-W.; Wang, G.-C.; Ma, Y.-H.; Zheng, H.; Luo, Y.-F.; Wei, Y.-Q.; Chen, L.-J. A Phosphoinositide 3-Kinase-γ Inhibitor AS605240 Prevents Bleomycin-Induced Pulmonary Fibrosis in Rats Biochem. Biophys. Res. Commun. 2010, 397, 311-317
63. van Dop, W. A.; Marengo, S.; te Velde, A. A.; Ciraolo, E.; Franco, I.; ten Kate, F. J.; Boeckxstaens, G. E.; Hardwick, J. C.; Hommes, D. W.; Hirsch, E.; van den Brink, G. R. The Absence of Functional PI3Kγ Prevents Leukocyte Recruitment and Ameliorates DSS-Induced Colitis in Mice Immunol. Lett. 2010, 131, 33-39
64. González-Garća, A.; Sánchez-Ruiz, J.; Flores, J. M.; Carrera, A. C. Phosphatidylinositol 3-Kinase γ Inhibition Ameliorates Inflammation and Tumor Growth in a Model of Colitis-Associated Cancer Gastroenterology 2010, 138, 1374-1383
65. Gruen, M.; Rose, C.; König, C.; Gajda, M.; Wetzker, R.; Bräuer, R. Loss of Phosphoinositide 3-Kinase γ Decreases Migration and Activation of Phagocytes but Not T-Cell Activation in Antigen-Induced Arthritis BMC Musculoskelatal Disord. 2010, 11, 1-11
66. Puri, K. D.; Steiner, B. H.; Kashishian, A. S.; Chen, H.; Gallatin, W. M.; Giese, N. A. IC87114, a Selective Inhibitor of PI3Kδ Suppresses Joint Inflammation and Bone Erosion in Collagen-Induced Arthritis in Rat J. Immunol. 2009, 182 (Suppl. 50) 14
67. Boyle, D. L.; Rommel, C.; Topolewski, K.; Firestein, G. S. A Novel PI3Kinase/Inhibitor Suppresses Collagen-Induced Arthritis Arthritis Rheum. 2009, 60 (Suppl. 10) 669
68. Hayer, S.; Pundt, N.; Peters, M. A.; Wunrau, C.; Kühnel, I.; Neugebauer, K.; Strietholt, S.; Zwerina, J.; Korb, A.; Penninger, J.; Joosten, L. A. B.; Gay, S.; Rückle, T.; Schett, G.; Pap, T. PI3Kγ Regulates Cartilage Damage in Chronic Inflammatory Arthritis FASEB J. 2009, 23, 4288-4298
69. Doukas, J.; Wrasidlo, W.; Noronha, G.; Dneprovskaia, E.; Fine, R.; Weis, S.; Hood, J.; Demaria, A.; Soll, R.; Cheresh, D. Phosphoinositide 3-Kinase γ/δ Inhibition Limits Infarct Size after Myocardial Ischemia/Reperfusion Injury Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 19866-19871
70. Siragusa, M.; Katare, R.; Meloni, M.; Damilano, F.; Hirsch, E.; Emanueli, C.; Madeddu, P. Involvement of Phosphoinositide 3-Kinase γ in Angiogenesis and Healing of Experimental Myocardial Infarction in Mice Circ. Res. 2010, 106, 757-768
71. Rodrigues, D. H.; de Carvalho Vilela, M.; da Silva Bacelos, L.; Pinho, V.; Teixeira, M. M.; Teixeira, A. L. Absence of PI3Kγ Leads to Increased Leukocyte Apoptosis and Diminished Severity of Experimental Autoimmune Encephalomyelitis J. Neuroimmunol. 2010, 222, 90-94
72. Barber, D. F.; Bartolomé, A.; Hernandez, C.; Flores, J. M.; Redondo, C.; Fernandez-Arias, C.; Camps, M.; Rückle, T.; Schwaarz, M. K.; Rodríguez, S.; Martinez-A, C.; Balomenos, D.; Rommel, C.; Carrera, A. C. PI3Kγ Inhibition Blocks Glomerulonephritis and Extends Lifespan in a Mouse Model of Systemic Lupus Nat. Med. 2005, 11, 933-935
73. Swat, W.; Montgrain, V.; Doggett, T. A.; Douangpanya, J.; Puri, K.; Vermi, W.; Diacovo, T. G. Essential Role of PI3Kδ and PI3Kγ in Thymocyte Survival Blood 2006, 107, 2415-2422
74. Randis, T. M.; Puri, K. D.; Zhou, H.; Diacovo, T. G. Role of PI3Kδ and PI3Kγ in Inflammatory Arthritis and Tissue Localization of Neutrophils Eur. J. Immunol. 2008, 38, 1215-1224
75. Rommel, C. Taking PI3Kδ and PI3Kγ One Step Ahead: Dual Active PI3Kδ/γ Inhibitors for the Treatment of Immune-Mediated Inflammatory Diseases. In Phosphoinositide 3-Kinase in Health and Disease; Rommel, C.; Vanhaesebroeck, B.; Vogt, P. K., Eds.; Current Topics in Microbiology and Immunology; Springer: New York, 2010; Vol. 1, pp 279-301.
76. Chuckowree, I.; Folkes, A.; Hancox, T.; Shuttleworth, S. Preparation of Substituted Thienopyrimidine as Inhibitor of Phosphatidylinositol 3-Kinase. WO2007129161A2, 2007.
77. National Institutes of Health. Identifier: NCT01493843; NCT01437566. ClinicalTrials.gov.
78. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A. E.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl- thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer J. Med. Chem. 2008, 51, 5522-5532
79. Baker, S. J.; Goldsmith, P. J.; Hancox, T. C.; Pegg, N. A.; Price, S.; Shuttleworth, S. J.; Sohal, S. Preparation of Thienopyrimidine Derivatives as PI3 Kinase Inhibitors. WO2007122410A1, 2007.
80. Hancox, T. C.; Pegg, N. A.; Nadin, A. J.; Price, S. Preparation of Thienopyrimidine Derivatives as Inhibitors of PI3 Kinase. WO2009053715A1, 2009.
81. Shuttleworth, S. J.; Folkes, A. J.; Chuckowree, I. S.; Wan, N. C.; Hancox, T. C.; Baker, S. J.; Sohal, S.; Latif, M. A. Preparation of Thienopyrimidines as Phosphatidylinositol 3 Kinase Inhibitors. WO2006046035A1, 2006.
82. Castanedo, G.; Goldstein, D.; Kondru, R. K.; Lucas, M.; Palmer, W.; Price, S.; Safina, B.; Savy, P. P. A.; Seward, E. M.; Sutherlin, D. P.; Sweeney, Z. K. Bicyclic Indole-pyrimidine PI3K Inhibitor Compounds Selective for P110 delta, and Methods of Use. U.S. Pat. Appl. 20100305084A1, 2010.
83. Li, J.; Safina, B.; Sutherlin, D. P.; Sweeney, Z. Preparation and Methods of Use of Purine Compounds Selective for PI3 Kinase p110 delta Isoform. WO2012007493A1, 2012.
84. Castanedo, G.; Chan, B.; Lucas, M. C.; Safina, B.; Sutherlin, D. P.; Sweeney, Z. K. Preparation of Pyrido[3,2- d ]pyrimidine as PI3Kδ Inhibitors. WO2011101429A1, 2011.
85. Castanedo, G.; Chan, B.; Goldstein, D. M.; Kondru, R. K.; Lucas, M. C.; Palmer, W. S.; Price, S.; Safina, B.; Savy, P. P. A.; Seward, E. M.; Sutherlin, D. P.; Sweeney, Z. K. Preparation of Bicyclic Pyrimidines as Selective Inhibitors of the p110 delta Isoform of PI3K for Treating Inflammation, Immune Diseases and Cancers. WO2010138589A1, 2010.
86. Bruce, I.; Weitz, S. G. Preparation of (Thiazolylureido)propionamides as Inhibitors of PI3K delta Enzyme. WO2008000421A2, 2008.
87. White, S. L. Thienopyrimidinones as δ-PI3K Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Inflammatory Disorders and Cancers. WO2008064018A1, 2008.
88. White, S. L.; Ruan, F.; Kesicki, E. A.; Thorsett, E.; Farouz, F. Preparation of Purine Pyrimidinone Compounds as Inhibitors of Human Phosphatidyl-Inositol 3-Kinase delta for Treating Immune, Inflammatory, and Other Diseases. WO2009064802A2, 2009.
89. Chen, Y.; Cushing, T. D.; Hao, X.; He, X.; Reichelt, A.; Rzasa, R. M.; Seganish, J.; Shin, Y.; Zhang, D. Heterocyclic Compounds and Their Uses in the Treatment of p110δ-Mediated Diseases and Their Preparation. WO2008118454A2, 2008.
90. Chen, Y.; Cushing, T. D.; Duquette, J. A.; Gonzalez, L. d. T. F.; Hao, X.; He, X.; Lucas, B.; McGee, L. R.; Reichelt, A.; Rzasa, R. M.; Seganish, J.; Shin, Y.; Zhang, D. Heterocyclic Compounds and Their Uses in the Treatment of p110δ-Mediated Diseases and Their Preparation. WO2008118468A1, 2008.
91. Cushing, T. D.; Dransfield, P. J.; Gonzalez, L. d. T. F.; Johnson, M. G.; Kohn, T. J.; Pattaropong, V.; Simard, J. L. Preparation of Heteroaryl Compounds as Inhibitors of PI3K Inhibitors. WO2010151791A1, 2010.
92. Brown, M.; Chen, Y.; Cushing, T. D.; Gonzalez, L. d. T. F.; He, X.; Kohn, T. J.; Lohman, J. W.; Pattaropong, V.; Seganish, J.; Shin, Y.; Simard, J. L. Preparation of Heterocyclic Compounds as Therapeutic PI3Kδ Inhibitors. WO2010151737A2, 2010.
93. Bui, M. H. T.; Chen, Y.; Cushing, T. D.; Duquette, J. A.; Fisher, B.; Gonzalez, L. d. T. F.; Hao, X.; He, X.; Johnson, M. G.; Lucas, B. Preparation of Quinolinylethylamino-pyrimidinecarbonitrile Derivative as Inhibitors of PI3K. WO2010151740A2, 2010.
94. Cushing, T. D.; Hao, X.; Lohman, J. W.; Shin, Y. Preparation of Pyrido[1,2- a ]pyrimidine and Quinoline Derivatives as Inhibitors of PI3K. WO2010151735A2, 2010.
95. Chen, Y.; Cushing, T. D.; Hao, X.; He, X.; Reichelt, A.; Rzasa, R. M.; Seganish, J.; Shin, Y.; Zhang, D. δ3-Substituted Quinoline or Quinoxaline Derivatives and Their Use as Phosphatidylinositol 3-kinase (PI3K) Inhibitors and Their Preparation. WO2008118455A1, 2008.
96. Cushing, T. D.; Duquette, J. A.; He, X.; Lohman, J. W.; Shin, Y. Preparation of Substituted Bicyclic Heteroaryl Compounds as PI3K Kinase Inhibitors. WO2011123751A2, 2011.
97. Lucas, B. Preparation of Thienopyridinylethylpurinamine Derivatives for Use as PI3K Activity Inhibitors. WO2012003262A1, 2012.
98. Cushing, T. D.; Gonzalez, L. d. T. F.; Hao, X.; Shin, Y. Heterocyclic Compounds as PI3K Inhibitors and Their Preparation and Use in the Treatment of Diseases. WO2011075628A1, 2011.
99. Duquette, J. A.; Lucas, B. Preparation of Quinoline Derivatives for Use as PI3K Inhibitors. WO2012003271A1, 2012.
100. Dransfield, P. J. Preparation of Quinoline Derivatives for Use as PI3K Inhibitors. WO2012003278A1, 2012.
101. Dransfield, P. J.; Gonzalez, L. d. T. F.; Kohn, T. J.; Pattaropong, V.; Simard, J. L. Preparation of Quinoline Derivatives for Use as PI3K Inhibitors. WO2012003283A1, 2012.
102. National Institutes of Health. Identifier: NCT01300026. ClinicalTrials.gov.
103. Intellikine Joins the Takeda Family of Companies. http://www.intellikine. com/.
104. Ren, P.; Liu, Y.; Wilson, T. E. Antitumor PI3 Kinase Modulators. WO2009046448A1, 2009.
105. Ren, P.; Liu, Y.; Wilson, T. E.; Chan, K.; Rommel, C.; Li, L. Preparation of Pyrazolo Pyrimidines and Purine Compounds as Therapeutic PI3 Kinase Modulators. WO2009088986A1, 2009.
106. Ren, P.; Liu, Y.; Wilson, T. E.; Li, L. Heterocyclic Compounds and Uses Thereof as Phosphatidylinositol 3′-Kinase Modulators. WO2010129816A2, 2010.
107. Ren, P.; Liu, Y.; Li, L.; Chan, K.; Wilson, T. E. Preparation of Benzothiazoles as Protein and Lipid Kinase Inhibitors. WO2009114874A2, 2009.
108. Ren, P.; Liu, Y.; Li, L.; Chan, K.; Wilson, T. E.; Martin, M.; Rommel, C. Preparation of 1 H -Pyrazolo[3,4- d ]pyrimidine Compounds as Kinase Inhibitors and Methods of Use as Therapeutic Agents. WO2010006086A2, 2010.
109. Bartok, B.; Boyle, D. L.; Liu, Y.; Ren, P.; Ball, S. T.; Bugbee, W. D.; Rommel, C.; Firestein, G. S. PI3 Kinase δ Is a Key Regulator of Synoviocyte Function in Rheumatoid Arthritis Am. J. Pathol. 2012, 180, 1906-1916
110. Knight, Z. A.; Shokat, K. M.; Williams, O. Preparation of Pyrazolopyrimidinylmethyl Quinazolinones as PI3 Kinase Antagonists. WO2008127226A2, 2008.
111. Berndt, A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. T.; Pacold, J. I.; Gorrec, F.; Hon, W.-C.; Liu, Y.; Rommel, C.; Gaillard, P.; Rückle, T.; Schwarz, M. K.; Shokat, K. M.; Shaw, J. P.; Williams, R. L. The P110δ Crystal Structure: Mechanisms for Selectivity and Potency of New PI(3)K Inhibitors Nat. Chem. Biol. 2010, 6, 117-124
112. Allen, D. R.; Buckley, G. M.; Buerli, R.; Davenport, R. J.; Kinsella, N.; Lock, C. J.; Lowe, C.; Mack, S. R.; Pitt, W. R.; Ratcliffe, A. J.; Richard, M. D.; Sabin, V. M.; Sharpe, A.; Tait, L. J.; Warrelow, G. J.; Williams, S. C. Preparation of Quinoxaline and Quinoline Derivatives as Kinase Inhibitors. WO2009081105A2, 2009.
113. Beevers, R. E.; Mack, S. R.; Sabin, V. M. Preparation of Quinoline Derivatives for Use as PI3 Kinase Inhibitors. WO2010061180A1, 2010.
114. Allen, D. R.; Brown, J. A.; Buerli, R.; Haughan, A. F.; MacDonald, J. D.; Matteucci, M.; Owens, A. P.; Raphy, G.; Saville-Stones, E. A.; Sharpe, A. Fused Pyridines and Related Compounds as Kinase Inhibitors and Their Preparation and Use for the Treatment of Diseases. WO2010092340A1, 2010.
115. Allen, D. R.; Brown, J. A.; Buerli, R.; Haughan, A. F.; Langham, B. J.; Matteucci, M.; Owens, A. P.; Raphy, G.; Sharpe, A. Preparation of Fused Bicyclic Pyrazole Derivatives as PI3 Kinase Inhibitors. WO2010133836A1, 2010.
116. Rewcastle, G. W.; Shepherd, P. R.; Chaussade, C.; Denny, W. A.; Gamage, S. A. Substituted Pyrimidines and Triazines as Inhibitors of PI3K Enzymes Useful in the Treatment of Cancer and Preparation and Pharmaceutical Compositions Thereof. WO2009120094A2, 2009.
117. Kawashima, S.; Matsuno, T.; Yaguchi, S.; Sasahara, H.; Watanabe, T. Preparation of Heterocyclic Compounds as Antitumor Agents. WO2002088112A1, 2002.
118. Yaguchi, S.; Fukui, Y.; Koshimizu, I.; Yoshimi, H.; Matsuno, T.; Gouda, H.; Hirono, S.; Yamazaki, K.; Yamori, T. Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor J. Natl. Cancer Inst. 2006, 98, 545-556
119. Kong, D.; Yamori, T. ZSTK474 is an ATP-Competitive Inhibitor of Class 1 Phosphatidylinositol 3-Kinase Isoforms Cancer Sci. 2007, 98, 1638-1642
120. Toyama, S.; Tamura, N.; Haruta, K.; Karakida, T.; Mori, S.; Watanabe, T.; Yamori, T.; Takasaki, Y. Inhibitory Effects of ZSTK474, a Novel Phosphoinositide 3-Kinase Inhibitor, on Osteoclasts and Collagen-Induced Arthritis in Mice Arthritis Res. Ther. 2010, 12 (R92) 1-11
121. Liang, C.; Li, Z.-G. Preparation of PI3K Isoform Selective Inhibitors. WO2010005558A2, 2010.
122. Ivashchenko, A. V.; Tkachenko, S. E.; Okun, I. Y. M.; Savchuk, N. F.; Ivashchenko, A. A.; Kravchenko, D. V.; Shmidt-Kittler, O.; Rago, K.; Papadopoulos, N.; Velcuelsu, V.; Vogelstein, B.; Kinzler, K. W.; Trifilenkov, A. S.; Rizhova, E. A.; Jiuxiang, Z. Annelated Azaheterocycles Comprising Pyrimidine Fragment, Method for the Production Thereof and (PI3Ks) Kinase Inhibitors. WO 2009011617A2, 2009.
123. Gaillard, P.; Quattropani, A.; Pomel, V.; Rueckle, T.; Klicic, J.; Church, D. Preparation of Pyrazine Derivatives, Particularly N -[3-(Oxyphenylamino)quinoxalin-2-yl]sulfonamides, as PI3K Inhibitors. WO2007023186A1, 2007.
124. Ren, P.; Liu, Y.; Li, L.; Chan, K.; Wilson, T. E. Preparation of Quinolinylmethylpyrazolopyrimidine Derivatives and Analogs for Use as Kinase Inhibitors. WO2010036380A1, 2010.
125. Takahashi, F.; Imada, S.; Shiwaku, M.; Kato, K.; Fukahori, H. Preparation of 2-(Difluoromethyl)-1-(morpholinoheterocyclyl)benzimidazole Derivatives as Selective Phosphatidyl Inositol-3-kinase (PI3Kδ) Inhibitors. WO2010092962A1, 2010.
126. Shuttleworth, S. J.; Silva, F. A.; Cecil, A. R. L.; Hill, T. J. Preparation of Benzo[1,3]oxazinone Derivatives as PI3 Kinase Inhibitors. WO2011012883A1, 2011.
127. Shuttleworth, S. J.; Silva, F. A. Preparation of Naphthyridine Derivatives as PI3K Inhibitors for the Treatment of Cancer and Immune-Inflammatory Diseases. WO2011135351A1, 2011.
128. Karus Therapeutics. http://www.karustherapeutics.com/.
129. Baldwin, I. R.; Down, K. D.; Faulder, P.; Gaines, S.; Hamblin, J. N.; Jones, K. L.; Le, J.; Lunniss, C. J.; Parr, N. J.; Ritchie, T. J.; Smethurst, C. A. P.; Washio, Y. Preparation of 4-Carboxamide Indazole Derivatives Useful as Inhibitors of PI3-Kinases. WO2009147187A1, 2009.
130. Hamblin, J. N.; Jones, P. S.; Keeling, S. E.; Le, J.; Mitchell, C. J.; Parr, N. J. Preparation of Oxazole-Substituted Indazole Derivatives for Use as PI3-Kinase Inhibitors. WO2010125082A1, 2010.
131. Baldwin, I. R.; Down, K. D.; Faulder, P.; Gaines, S.; Hamblin, J. N.; Le, J.; Lunniss, C. J.; Parr, N. J.; Ritchie, T. J.; Robinson, J. E.; Simpson, J. K.; Smethurst, C. A. P. Preparation of N -Indazolyl Carboxamides as PI3-Kinase Inhibitors. WO2011067364A1, 2011.
132. Hamblin, J. N.; Jones, P. S.; Keeling, S. E.; Le, J.; Mitchell, C. J.; Parr, N. J.; Willacy, R. D. Preparation of Polymorphs and Salts of cis-N -[5-[4-[5-[[2,6-Dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1 H -indazol-6-yl]-2-methoxy-3-pyridinyl]-methanesulfonamide as PI3Kδ Inhibitors. WO2012032067A1, 2012.
133. National Institutes of Health. Identifier: NCT01462617. ClinicalTrials.gov.
134. Muthuppalaniappan, M.; Viswanadha, S.; Babu, G.; Vakkalanka, S. K. V. S. Preparation of Chromen-4-one Compounds as Therapeutic PI3K Kinase Modulators. WO2011055215A2, 2011.
135. King-Underwood, J.; Ito, K.; Murray, P. J.; Hardy, G.; Brookfield, F. A.; Brown, C. J. Preparation of Pyrazolopyrimidine Compounds as Phosphoinositide 3-Kinase (PI3 Kinase) Inhibitors. WO2011048111A1, 2011.
136. Li, Y.-L.; Metcalf, B. W.; Combs, A. P. Preparation of Pyrimidinones as PI3K Inhibitors. WO2011008487A1, 2011.
137. Combs, A. P.; Li, Y.-L.; Yue, E. W.; Sparks, R. B. Preparation of Substituted Heteroaryl Fused Derivatives as PI3K Inhibitors. WO2011075643A1, 2011.
138. Combs, A. P.; Sparks, R. B.; Yue, E. W. Preparation of Imidazopyridinylethylpurinamine Derivatives and Analogs for Use as PI3K Inhibitors. WO2011130342A1, 2011.
139. Li, Y.-L.; Combs, A. P. Fused Pyrrole Derivatives as PI3K Inhibitors U.S. Pat. Appl. 20110312979A1, 2011.
140. Li, Y.-L.; Combs, A. P.; Yue, E. W.; Li, H.-Y. Preparation of Substituted Fused Aryl and Heteroaryl Derivatives as PI3K Inhibitors. WO2011075630A1, 2011.
141. Pathway Therapeutics. http://www.pathwaytx.com/.
142. Mattheakis, L.; Kearney, P.; Jaegar, C.; Plonowski, A.; Zhang, J.; Yu, P. Presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, November 16-19, 2010; Abstract 219.
143. Kearney, P. Preparation of Heterocyclyl-Substituted Purine Derivatives as Inhibitors of PI3K-delta for the Treatment of Cancer. WO2012037226A1, 2012.
144. Leahy, J. W. Preparation of Heterocyclyl-Substituted Purine Derivatives as Inhibitors of PI3K-delta for the Treatment of Cancer. WO2012037204A1, 2012.
145. Fowler, K. W.; Huang, D.; Kesicki, E. A.; Ooi, H. C.; Oliver, A. R.; Ruan, F.; Treiberg, J. Preparation of Purine Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase delta. WO2005113556A1, 2005.
146. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Perrone, G.; Miura, N.; Yasui, H.; Okawa, Y.; Kiziltepe, T.; Santo, L.; Vallet, S.; Cristea, D.; Calabreseqq, E.; Gorgun, G.; Raje, N. S.; Richardson, P.; Munshi, N. C.; Lannutti, B. J.; Puri, K. D.; Giese, N. A.; Anderson, K. C. PI3K/p110δ Is a Novel Therapeutic Target in Multiple Myeloma Blood 2010, 116, 1460-1468
147. Gallatin, M. W.; Ulrich, R. G.; Giese, N. Use of Quinazoline Derivatives for the Treatment of Hematologic Malignancies, Inflammatory and Autoimmune Disorders. WO2010057048A1, 2010.
148. Flinn, I. W.; Byrd, J. C.; Furman, R. R.; Brown, J. R.; Benson, D. M.; Coutre, S. E.; Kahl, B. S.; Smith, B. D.; Wagner-Johnston, N. D.; Spurgeon, S. E.; Giese, N. A.; Yu, A. S. Presented at the American Society of Hematology Annual Meeting, New Orleans, LA, U.S., 2009; Abstract 922.
149. Webb, H. K; Chen, H.; Yu, A. S.; Peterman, S.; Holes, L.; Lannutti, B.; Miller, L. L.; Ulrich, R. G. Presented at the American Society of Hematology Annual Meeting, Orlando, FL, U.S., 2010; Abstract 1774.
150. National Institutes of Health. Identifier: NCT00836914, ClinicalTrials.gov.
151. National Institutes of Health. Identifier: NCT01066611. ClinicalTrials.gov.
152. Ulrich, R. G. Treatment of Liver Disorders with PI3K Inhibitors. WO2011011550A1, 2011.
153. Sadhu, C.; Dick, K.; Tino, W. T.; Staunton, D. E. Selective Role of PI3Kδ in Neutrophil Inflammatory Responses Biochem. Biophys. Res. Commun. 2003, 308, 764-769
154. Quattropani, A.; Dorbais, J.; Covini, D.; Desforges, G.; Rueckle, T. Thiazole Derivatives and Use Thereof. U.S. Pat. Appl. 20080188531A1, 2008.
155. Barvian, N. C.; Kolz, C. N.; Para, K. S.; Patt, W. C.; Visnick, M. Preparation of Benzoxazin-3-ones and Derivatives as Inhibitors of PI3K Kinase for Treating Inflammations, Cardiovascular Diseases and Cancers. WO2004052373A1, 2004.
156. Connolly, M.; Gogliotti, R. D.; Lee, H. T.; Plummer, M. S.; Sexton, K. E.; Visnick, M. Preparation of N -Tetrazolyl Benzo[ b ]thiophenecarboxamides as Phosphoinositide-3-kinase (PI3K) Inhibitors for the Treatment of Cancer, Inflammatory and Cardiovascular Diseases. WO2004108713A1, 2004.
157. Connolly, M. K.; Gogliotti, R. D.; Plummer, M. S.; Visnick, M. Preparation of Morpholinyl-Pyrimidine Derivatives as Inhibitors of Phosphoinositide-3-kinases. WO2005042519A1, 2005.
158. Wilson, F.; Ramsden, N.; Bell, K.; Cansfield, A.; Burckhardt, S.; Taylor, J.; Sunose, M.; Middlemiss, D. Preparation of (Aryltriazolopyridinyl)amine Derivatives for Use as Kinase Inhibitors. WO2008025821A1, 2008.
159. Wang, T.; Green, J.; Cornebise, M.; Ledford, B.; Parsons, J.; Tanner, A.; Westcott, J. Preparation of Thiazolyl Furan-2-carboxylate Derivatives as Inhibitors of Phosphatidylinositol 3-Kinase. WO2008027584A2, 2008.
160. Aronov, A.; Bandarage, U. K.; Cottrell, K.; Davies, R.; Krueger, E.; Ledeboer, M.; Ledford, B.; Le, T. A.; Liao, Y.; Messersmith, D.; Wang, T.; Xu, J. Preparation of Tetrahydrothiazolopyridine Derivatives for Use as Phosphatidylinositol 3-Kinase Inhibitors. WO2010096389A1, 2010.
161. Wang, T.; Aronov, A.; Cornebise, M.; Maltais, F.; Ledoboer, M.; Le, T. A.; Marone, V.; Messersmith, D.; Cottrell, K. Pyridinylbenzothiazole-urea Derivatives as Phosphatidylinositol 3-Kinase Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Diseases. WO2009129211A1, 2009.
162. Aronov, A.; Come, J.; Cottrell, K.; Grey, R.; LeTiran, A.; Marone, V.; Martinez-Botella, G.; Messersmith, D.; Huck, E. P. Preparation of Benzothiazole Derivatives for Use as PI3K Inhibitors and Useful in the Treatment of Autoimmune Diseases. WO2010135014A1, 2010.
163. Bruce, I.; Hayler, J. F.; Bloomfield, G. C.; Edwards, L.; Cox, B.; Howsham, C. Preparation of Pyrazolo[3,4- d ]pyrimidine Derivatives for Treating Respiratory Disorders. WO2007134828A1, 2007.
164. Bloomfield, G. C.; Bruce, I.; Hayler, J. F.; Leblanc, C.; Le, G. D. M.; McCarthy, C. Preparation of Phenylthiazolylureas as Inhibitors of Phosphatidylinositol 3-Kinase. WO2005021519A2, 2005.
165. Bruce, I.; Budd, E.; Edwards, L.; Howsham, C. Preparation of Pyrazine Compounds as Inhibitors of Phosphatidylinositol 3-Kinase Enzymes in the Treatment of Inflammatory and Allergic Conditions. WO2009115517A2, 2009.
166. Moffat, D. C. F.; Davies, S.; Alesso, S. M.; Launay, D. F. M. Preparation of 4-Methyl-5-(alkylsulfonylphenyl)thiazoles, Particularly Amino Acid Derivatives of Thiazoles, as Inhibitors of PI3 Kinase Useful for Treating Autoimmune, Inflammatory and Proliferative Diseases. WO2007129048A1, 2007.
167. Grauert, M.; Maier, U.; Hoffmann, M.; Scheuerer, S.; Joergensen, A. T.; Pautsch, A.; Brandl, T.; Hoenke, C.; Breitfelder, S.; Erb, K.; Pieper, M.; Pragst, I. Thiazolyl-dihydro-indazoles. U.S. Pat. Appl. 20090093474A1, 2009.
168. Rueckle, T.; Quattropani, A.; Pomel, V.; Dorbais, J.; Covini, D.; Bischoff, A. Preparation of Pyridine Methylene Thioxothiazolidinones as Phosphoinositide Inhibitors. WO2006024666A1, 2006.
169. Taniyama, D.; Kano, K.; Ishibashi, K.; Endoh, T. Preparation of Pyrimidine Derivative and Pyridine Derivative Both Having Phosphatidyl Inositol-3 Kinase (PI3K) Inhibitory Activity. WO2010061903A1, 2010.
170. Fujioka, M.; Mitsumori, S.; Kugimiya, A.; Taniyama, D. Preparation of 3,4-Dihydro-2 H -pyrido[3,2- b ]-1,4-oxazine Derivatives as PI3K Inhibitors for Treatment of Inflammation. WO2010027002A1, 2010.
171. Leahy, J. W.; Buhr, C. A.; Johnson, H. W. B.; Kim, B. G.; Baik, T.; Cannoy, J.; Forsyth, T. P.; Jeong, J. W.; Lee, M. S.; Ma, S.; Noson, K.; Wang, L.; Williams, M.; Nuss, J. M.; Brooks, E.; Foster, P.; Goon, L.; Heald, N.; Holst, C.; Jaeger, C.; Lam, S.; Lougheed, J.; Nguyen, L.; Plonowski, A.; Song, J.; Stout, T.; Wu, X.; Yakes, M. F.; Yu, P.; Zhang, W.; Lamb, P.; Raeber, O. Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors J. Med. Chem. 2012, 55, 5467-5482
172. Alexander, R.; Balasundaram, A.; Batchelor, M.; Brookings, D.; Crépy, K.; Crabbe, T.; Deltent, M.-F.; Driessens, F.; Gill, A.; Harris, S.; Hutchinson, G.; Kulisa, C.; Merriman, M.; Mistry, P.; Parton, T.; Turner, J.; Whitcombe, I.; Wright, S. 4-(1,3-Thiazol-yl)morpholine Derivative as Inhibitors of Phosphoinositide 3-Kinase Bioorg. Med. Chem. Lett. 2008, 18, 4316-4320
173. Perry, B.; Alexander, R.; Bennett, G.; Buckley, G.; Ceska, T.; Crabbe, T.; Dale, V.; Gowers, L.; Horsley, H.; James, L.; Jenkins, K.; Crépy, K.; Kulisa, C.; Lightfoot, H.; Lock, C.; Mack, S.; Morgan, T.; Nicolas, A.-L.; Pitt, W.; Sabin, V.; Wright, S. Achieving Multi-Isoform PI3K Inhibition in a Series of Substituted 3,4-Dihydro-2 H -benzo{1,4}oxazines Bioorg. Med. Chem. Lett. 2008, 18, 4700-4704
174. Perry, B.; Beevers, R.; Bennett, G.; Buckley, G.; Crabbe, T.; Gowers, L.; James, L.; Jenkins, K.; Lock, C.; Sabin, V.; Wright, S. Optimization of a Series of Multi-Isoform PI3 Kinase Inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 5299-5302
175. Cardin, D. P.; Gaulin, J. L.; Greenspan, P. D.; Vyskocil, S.; Xu, T.; Renou, C. C. Preparation of Thiophene or Thiazole Derivatives and Their Use as PI3K Inhibitors. WO2009154741A1, 2009.
176. Baldwin, I. R.; Down, K. D.; Faulder, P.; Gaines, S.; Hamblin, J. N.; Le, J.; Lunniss, C. J.; Parr, N. J.; Ritchie, T. J.; Simpson, J. K.; Smethurst, C. A. P. Preparation of 4-Amino-1 H -indazole Compounds as Inhibitors of PI3-Kinases for Treatment of Asthma and COPD. WO2009147190A1, 2009.
177. Baldwin, I. R.; Down, K. D.; Faulder, P.; Gaines, S.; Hamblin, J. N.; Jones, P. S.; Le, J.; Parr, N. J.; Ritchie, T. J.; Robinson, J. E.; Simpson, J. K.; Smethurst, C. A. P. Preparation of Indolylindazole Derivatives for Use as PI3-Kinase Inhibitors. WO2009147189A1, 2009.
178. Hamblin, J. N.; Harrison, Z. A.; Jones, P. S.; Keeling, S. E.; Le, J.; Lunniss, C. J.; Parr, N. J. Preparation of 4-(Oxadiazol-2-yl)indazoles as Inhibitors of PI3 Kinase. WO2010102958A1, 2010.
179. Baldwin, I. R.; Down, K. D.; Faulder, P.; Gaines, S.; Hamblin, J. N.; Le, J.; Lunniss, C. J.; Parr, N. J.; Ritchie, T. J.; Robinson, J. E.; Simpson, J. K.; Smethurst, C. A. P. Benzopyrazole Derivatives as PI3 Kinase Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Diseases. WO2009147188A1, 2009.
180. Baldwin, I. R.; Down, K. D.; Faulder, P.; Gaines, S.; Hamblin, J. N.; Jones, K. L.; Jones, P. S.; Le, J.; Lunniss, C. J.; Parr, N. J.; Ritchie, T. J.; Robinson, J. E.; Simpson, J. K.; Smethurst, C. A. P. Indazole Derivatives as PI3 Kinase Inhibitors and Their Preparation and Use for the Treatment of PI3 Kinase-Mediated Diseases. WO2011067365A1, 2011.
181. Baldwin, I. R.; Down, K. D.; Faulder, P.; Gaines, S.; Hamblin, J. N.; Jones, K. L.; Le, J.; Lunniss, C. J.; Parr, N. J.; Ritchie, T. J.; Robinson, J. E.; Smethurst, C. A. P. Indazole Derivatives as PI3 Kinase Inhibitors and Their Preparation and Use for the Treatment of PI3 Kinase-Mediated Diseases. WO2011067366A1, 2011.
182. Williams, O.; Houseman, B. T.; Kunkel, E. J.; Aizenstein, B.; Hoffman, R.; Knight, Z. A.; Shokat, K. M. Discovery of Dual Inhibitors of the Immune Cell PI3Ks P110δ and P110γ: A Prototype for New Anti-Inflammatory Drugs Chem. Biol. 2010, 17, 123-134
183. Ren, P.; Liu, Y.; Wilson, T. E.; Chan, K.; Rommel, C.; Li, L. Preparation of Pyrazolo Pyrimidines and Other Heterocyclic Compounds as Therapeutic PI3 Kinase Modulators. WO2009088990A1, 2009.
184. Infinity Pharmaceuticals. http://www.infi.com/.
185. Ihle, N T.; Powis, G. Take Your PIK: Phosphatidylinositol 3-Kinase Inhibitors Race through the Clinic and toward Cancer Therapy Mol. Cancer Ther. 2009, 8, 1-9
186. Walker, E. H.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R. L. Structural Insights into Phosphoinositide 3-Kinase Catalysis and Signaling Nature 1999, 402, 313-320
187. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin LY294002, Quercetin, Myricetin, and Staurosporine Mol. Cell 2000, 6, 909-919
188. Akritopoulou-Zanze, I.; Hajduk, P. J. Kinase-Targeted Libraries: The Design and Synthesis of Novel, Potent, and Selective Kinase Inhibitors Drug Discovery Today 2009, 14, 291-297
189. Zhang, X.; Vadas, O.; Perisic, O.; Anderson, K. E.; Clark, J.; Hawkins, P. T.; Stephens, L. R.; Williams, R. L. Structure of Lipid p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism Mol. Cell 2011, 41, 567-578
190. Hon, W. C.; Berndt, A.; Williams, R. L. Regulation of Lipid Binding Underlies the Activation Mechanism of Class IA PI3-Kinases Oncogene 2012, 31, 3655-3666
191. Huang, C.-H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V. E.; Kinzler, K. W.; Vogelstein, B.; Gabelli, S. B.; Amzel, L. M. The Structure of a Human p110 α /p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations Science 2007, 318, 1744-1748
192. Mandelker, D.; Gabelli, S. B.; Schmidt-Kittler, O.; Zhu, J.; Cheong, I.; Huang, C.-H.; Kinzler, K. W.; Vogelstein, B.; Amzel, L. M. A Frequent Kinase Domain Mutation That Changes the Interaction between PI3Kα and the Membrane Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16996-17001
193. Amzel, L. M.; Huang, C.-H.; Mandelker, D.; Lengauer, C.; Gabelli, S. B.; Vogelstein, B. Structural Comparisons of Class I Phosphoinositide 3-Kinases Nat. Rev. Cancer 2008, 8, 665-669
194. Kuang, R.-R.; Qian, F.; Li, Z.; Wei, D.-Z. Study on Improving the Selectivity of Compounds That Inhibit Two PI3Ks (gamma and delta) J. Mol. Model. 2006, 12, 445-452
195. Zvelebil, M. J.; Waterfield, M. D.; Shuttleworth, S. J. Structural Analysis of PI3-Kinase Isoforms: Identification of Residues Enabling Selective Inhibition by Small Molecule ATP-Competitive Inhibitors Arch. Biochem. Biophys. 2008, 477, 404-410
196. Sinnamon, R. H.; McDevitt, P.; Pietrak, B. L.; Leydon, V. R.; Xue, Y.; Lehr, R.; Qi, H.; Burns, M.; Elkins, P.; Ward, P.; Vincentini, G.; Fisher, D.; Grimes, M.; Brandt, M.; Auger, K. R.; Ho, T.; Johanson, K.; Jones, C. S.; Schwartz, B.; Sweitzer, T,.D.; Kirkpatrick, R. B. Baculovirus Production of Fully-Active Phosphoinositide 3-Kinase alpha as a p85 α-p110 α Fusion for X-ray Crystallographic Analysis with ATP Competitive Enzyme Inhibitors Protein Expression Purif. 2010, 73, 167-176